TY - JOUR
T1 - Short Communication
T2 - Plasma Lymphocyte Activation Gene 3 and Subclinical Coronary Artery Disease in the Multicenter AIDS Cohort Study
AU - Sarkar, Sudipa
AU - Haberlen, Sabina
AU - Post, Wendy S.
AU - Kelesidis, Theodoros
AU - Wiley, Dorothy
AU - Kingsley, Lawrence
AU - Kim, Eun Young
AU - Palella, Frank J.
AU - Witt, Mallory D.
AU - Budoff, Matthew J.
AU - Rodriguez, Annabelle
AU - Brown, Todd T.
N1 - Funding Information:
The authors gratefully acknowledge the contributions of the study participants and dedication of the staff at the MACS/WIHS Combined Cohort Study (MWCCS) sites. Data in this article were collected by MACS and WIHS, now the MWCCS, which is supported by the National Institutes of Health (NIH). The contents of this publication are solely the responsibility of the authors and do not represent the official views of the NIH. MWCCS (Principal Investigators): Baltimore CRS (Todd Brown and Joseph Margolick), U01-HL146201; Data Analysis and Coordination Center (Gypsyamber D’Souza, Stephen Gange, and Elizabeth Go-lub), U01-HL146193; Chicago-Cook County CRS (Mardge Cohen and Audrey French), U01-HL146245; Chicago-Northwestern CRS (Steven Wolinsky), U01-HL146240; Northern California CRS (Bradley Aouizerat, Jennifer Price, and Phyllis Tien), U01-HL146242; Los Angeles CRS (Roger Detels and Matthew Mimiaga), U01-HL146333; Metropolitan Washington CRS (Seble Kassaye and Daniel Merenstein), U01-HL146205; and Pittsburgh CRS ( Jeremy Martinson and Charles Rinaldo), U01-HL146208. The MWCCS is funded primarily by the National Heart, Lung, and Blood Institute (NHLBI), with additional co-funding from the Eunice Kennedy Shriver National Institute Of Child Health & Human Development (NICHD), National Institute On Aging (NIA), National Institute Of Dental & Craniofacial Research (NIDCR), National Institute Of Allergy And Infectious Diseases (NIAID), National Institute Of Neurological Disorders And Stroke (NINDS), National Institute Of Mental Health (NIMH), National Institute On Drug Abuse (NIDA), National Institute Of Nursing Research (NINR), National Cancer Institute (NCI), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Minority Health and Health Disparities (NIMHD), and in coordination and alignment with the research priorities of the NIH, Office of AIDS Research (OAR). MWCCS data collection is also supported by UL1-TR000004 (UCSF CTSA), UL1-TR003098 ( JHU ICTR), UL1-TR001881 (UCLA CTSI), P30-AI-073961 (Miami CFAR), P30-AI-050410 (UNC CFAR), P30-AI-027767 (UAB CFAR), and UL1-RR033176 (Lundquist Institute at Harbor-UCLA).
Publisher Copyright:
© Copyright 2021, Mary Ann Liebert, Inc., publishers 2021.
PY - 2021/11/1
Y1 - 2021/11/1
N2 - Chronic inflammation, including among people with HIV (PWH), elevates immune cell expression of lymphocyte activation gene 3 (LAG3); however, low plasma LAG3 predicts cardiovascular disease (CVD) events in the general population. The associations among LAG3 plasma levels, subclinical atherosclerosis, inflammation, and HIV infection have not been well described. We measured plasma LAG3 in 704 men with and without HIV from the multicenter AIDS cohort study, who underwent coronary computed tomography angiography. HIV serostatus was not independently associated with LAG3 after adjustment for sociodemographic and CVD risk factors. Current smoking status and African American race were associated with lower LAG3, and age and sTNFαRI concentration were associated with greater LAG3. LAG3 was not associated with coronary artery stenosis. Thus, no difference was found in plasma LAG3 concentration by HIV serostatus, and no association between LAG3 and subclinical coronary atherosclerosis in men with and without HIV was observed.
AB - Chronic inflammation, including among people with HIV (PWH), elevates immune cell expression of lymphocyte activation gene 3 (LAG3); however, low plasma LAG3 predicts cardiovascular disease (CVD) events in the general population. The associations among LAG3 plasma levels, subclinical atherosclerosis, inflammation, and HIV infection have not been well described. We measured plasma LAG3 in 704 men with and without HIV from the multicenter AIDS cohort study, who underwent coronary computed tomography angiography. HIV serostatus was not independently associated with LAG3 after adjustment for sociodemographic and CVD risk factors. Current smoking status and African American race were associated with lower LAG3, and age and sTNFαRI concentration were associated with greater LAG3. LAG3 was not associated with coronary artery stenosis. Thus, no difference was found in plasma LAG3 concentration by HIV serostatus, and no association between LAG3 and subclinical coronary atherosclerosis in men with and without HIV was observed.
KW - HIV
KW - LAG3
KW - cardiovascular disease
UR - http://www.scopus.com/inward/record.url?scp=85118935990&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85118935990&partnerID=8YFLogxK
U2 - 10.1089/aid.2021.0035
DO - 10.1089/aid.2021.0035
M3 - Article
C2 - 34384260
AN - SCOPUS:85118935990
SN - 0889-2229
VL - 37
SP - 842
EP - 845
JO - AIDS Research and Human Retroviruses
JF - AIDS Research and Human Retroviruses
IS - 11
ER -
